Pfizer-backed Mediar Therapeutics ropes in another Big Pharma investor
A biotech centered on treating fibrosis — born out of Mass General and Brigham and Women’s Hospital — has received a financial boost.
According to an SEC filing, the company has raised $31,761,186 in its latest funding round, which includes 17 investors. The filing lists six names attached to the company, including Meredith Fisher, a partner at Mass General Brigham Ventures and Mediar’s acting CEO.
Other names in the filing include Peter Parker, the managing general partner at Mission BioCapital, and Michael Baran, a partner at Pfizer Ventures, who are members of Mediar’s board. Nandita Shangari, managing director of the Novartis Venture Fund; Maina Bhaman, a partner at Sofinnova Ventures; and Andreas Jurgeit, a partner at Gimv, were also listed on the document.
Endpoints News has reached out for more information on the funding. In an email, Fisher said that Mediar is not commenting at this time.
Mediar, which was founded by Mass General Brigham Ventures and researchers from the institution in 2019, is still in the preclinical stage. The biotech is developing candidates to try and halt or reverse fibrosis by using the cell known as the myofibroblast.
The biotech raised a seed extension in 2021, which brought on Pfizer Ventures and Ono Venture Investment as new members to bring the total backing to $20 million. Mass General Brigham Ventures led the initial seed round in 2019, along with other investors, to support a discovery platform and the development of antibody treatments.
This was not Pfizer’s first go-around with the company. In 2019, Mediar was selected as the winner of the Pfizer Golden Ticket Program, providing the biotech with some bench space at LabCentral, a shared laboratory space that is meant to act as a launchpad for startups. The site is located in Cambridge, MA, and is close to Pfizer’s presence in Kendall Square.
Last year, Ex-Kymab CEO Simon Sturge was also brought onto the team at Mediar as executive chairman.